Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $7.88 Average Price Target from Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has received a consensus recommendation of “Buy” from the five brokerages that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $7.8750.

Several equities analysts recently weighed in on PSTV shares. D Boral Capital raised shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd. Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. D. Boral Capital raised shares of Plus Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Wednesday, September 3rd. Ascendiant Capital Markets raised their price objective on shares of Plus Therapeutics from $20.00 to $20.50 and gave the company a “buy” rating in a research report on Thursday, June 5th. Finally, HC Wainwright dropped their price target on shares of Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 27th.

Plus Therapeutics Stock Performance

PSTV stock opened at $0.45 on Friday. The stock has a market cap of $44.40 million, a P/E ratio of -0.20 and a beta of 0.66. The firm has a 50 day simple moving average of $0.50 and a 200 day simple moving average of $0.59. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.08. The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $1.08 million. Sell-side analysts predict that Plus Therapeutics will post -2.3 EPS for the current year.

Insider Activity at Plus Therapeutics

In other news, Director Robert P. Lenk purchased 110,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of $0.49 per share, with a total value of $53,900.00. Following the completion of the transaction, the director directly owned 139,327 shares in the company, valued at $68,270.23. This trade represents a 375.08% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Virtu Financial LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 0.24% of Plus Therapeutics at the end of the most recent quarter. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.